This is a Validated Antibody Database (VAD) review about bovine PRF1, based on 17 published articles (read how Labome selects the articles), using PRF1 antibody in all methods. It is aimed to help Labome visitors find the most suited PRF1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
BioLegend
mouse monoclonal (dG9)
  • immunohistochemistry; mouse; loading ...; fig 2a
BioLegend PRF1 antibody (BioLegend, dG9) was used in immunohistochemistry on mouse samples (fig 2a). elife (2020) ncbi
mouse monoclonal (dG9)
  • immunocytochemistry; human; 1:50; loading ...; fig 4a, 7a
BioLegend PRF1 antibody (Biolegend, 308108) was used in immunocytochemistry on human samples at 1:50 (fig 4a, 7a). elife (2020) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; 1:50; loading ...; fig 2b
  • immunocytochemistry; human; loading ...; fig 2a
BioLegend PRF1 antibody (Biolegend, dG9) was used in flow cytometry on human samples at 1:50 (fig 2b) and in immunocytochemistry on human samples (fig 2a). Sci Signal (2020) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; loading ...; fig 2a
BioLegend PRF1 antibody (Biolegend, dG9) was used in flow cytometry on human samples (fig 2a). Front Immunol (2019) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; loading ...; fig 1j
BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples (fig 1j). PLoS Pathog (2018) ncbi
mouse monoclonal (dG9)
  • other; human; loading ...; fig 1b
BioLegend PRF1 antibody (BioLegend, dG9) was used in other on human samples (fig 1b). J Cell Biol (2018) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; loading ...; fig 3a
In order to use CD49a expression to define subsets of tissue-resident memory T cells in the skin, BioLegend PRF1 antibody (Biolegend, dG9) was used in flow cytometry on human samples (fig 3a). Immunity (2017) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; fig 1e
In order to investigate the role of Eomes in the retention of liver natural killer cells, BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples (fig 1e). J Immunol (2016) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; 5 ug/ml; fig 5
BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples at 5 ug/ml (fig 5). Nat Commun (2016) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; loading ...; fig s1
In order to characterize innate lymphoid cell subpopulations isolated from patients with systemic sclerosis, BioLegend PRF1 antibody (biolegend, dG9) was used in flow cytometry on human samples (fig s1). J Immunol (2016) ncbi
mouse monoclonal (dG9)
  • immunocytochemistry; human; fig 8
In order to study how DNAM-1 controls NK cell-mediated cytotoxicity and cytokine production, BioLegend PRF1 antibody (BioLegend, dG9) was used in immunocytochemistry on human samples (fig 8). J Exp Med (2015) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human
BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples . Clin Cancer Res (2016) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; 2.5 mg/ml; fig 3
BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples at 2.5 mg/ml (fig 3). J Surg Res (2015) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human; fig 4
BioLegend PRF1 antibody (Biolegend, dG9) was used in flow cytometry on human samples (fig 4). Eur J Immunol (2015) ncbi
mouse monoclonal (dG9)
  • immunocytochemistry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, BioLegend PRF1 antibody (BioLegend, DG9) was used in immunocytochemistry on human samples . Cancer Res (2014) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human
BioLegend PRF1 antibody (Biolegend, clone dG9) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (dG9)
  • flow cytometry; human
BioLegend PRF1 antibody (BioLegend, dG9) was used in flow cytometry on human samples . Clin Cancer Res (2012) ncbi
Articles Reviewed
  1. Chitirala P, Chang H, Martzloff P, Harenberg C, Ravichandran K, Abdulreda M, et al. Studying the biology of cytotoxic T lymphocytes in vivo with a fluorescent granzyme B-mTFP knock-in mouse. elife. 2020;9: pubmed publisher
  2. Gunesch J, Dixon A, Ebrahim T, Berrien Elliott M, Tatineni S, Kumar T, et al. CD56 regulates human NK cell cytotoxicity through Pyk2. elife. 2020;9: pubmed publisher
  3. Zurli V, Montecchi T, Heilig R, Poschke I, Volkmar M, Wimmer G, et al. Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Sci Signal. 2020;13: pubmed publisher
  4. Ingegnere T, Mariotti F, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front Immunol. 2019;10:957 pubmed publisher
  5. Ye W, Chew M, Hou J, Lai F, Leopold S, Loo H, et al. Microvesicles from malaria-infected red blood cells activate natural killer cells via MDA5 pathway. PLoS Pathog. 2018;14:e1007298 pubmed publisher
  6. Srpan K, Ambrose A, Karampatzakis A, Saeed M, Cartwright A, Guldevall K, et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol. 2018;217:3267-3283 pubmed publisher
  7. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang S, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017;46:287-300 pubmed publisher
  8. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  9. Khazen R, Müller S, Gaudenzio N, Espinosa E, Puissegur M, Valitutti S. Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. Nat Commun. 2016;7:10823 pubmed publisher
  10. Roan F, Stoklasek T, Whalen E, Molitor J, Bluestone J, Buckner J, et al. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016;196:2051-2062 pubmed publisher
  11. Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212:2165-82 pubmed publisher
  12. Rosario M, Liu B, Kong L, Collins L, Schneider S, Chen X, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016;22:596-608 pubmed publisher
  13. Zhang P, Lu X, Tao K, Shi L, Li W, Wang G, et al. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. J Surg Res. 2015;194:107-13 pubmed publisher
  14. Ziblat A, Domaica C, Spallanzani R, Iraolagoitia X, Rossi L, Avila D, et al. IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol. 2015;45:192-202 pubmed publisher
  15. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  16. Poonia B, Pauza C. Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS ONE. 2014;9:e88884 pubmed publisher
  17. Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-70 pubmed publisher